Jon Graves, Ph.D.

Head of Research

Jon Graves, Ph.D. joined Archon Biosciences as head of research in 2023. Prior to Archon, he was part of the management team at IFM Therapeutics that, over a 5 year period, raised $113M of funding, brought four programs from a standing start through to the clinic, and closed three major deals totaling $4.7B. Earlier in his career, Jon led the biology team at TCR2 and built the immunotherapy portfolio at Tesaro that was subsequently sold to GSK for $5.1B.  

Jon completed his doctorate in the laboratory of Doreen Cantrell, Ph.D. at Cancer Research UK in 1991 before moving to the United States for postdoctoral studies with Frank McCormick, Ph.D. at Onyx Pharmaceuticals and Nobel Laureate Edwin Krebs, Ph.D. at the University of Washington in Seattle. He became a member of Faculty in the UW Department of Immunology in 1998 before making the jump to industry by joining Amgen’s Seattle Oncology group in 2004.  

---